IL312124A - Eukaryotic cells containing adenovirus polynucleotides - Google Patents

Eukaryotic cells containing adenovirus polynucleotides

Info

Publication number
IL312124A
IL312124A IL312124A IL31212424A IL312124A IL 312124 A IL312124 A IL 312124A IL 312124 A IL312124 A IL 312124A IL 31212424 A IL31212424 A IL 31212424A IL 312124 A IL312124 A IL 312124A
Authority
IL
Israel
Prior art keywords
adenovirus
eukaryotic cells
associated virus
virus polynucleotides
polynucleotides
Prior art date
Application number
IL312124A
Other languages
English (en)
Hebrew (he)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL312124A publication Critical patent/IL312124A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL312124A 2021-10-18 2022-10-18 Eukaryotic cells containing adenovirus polynucleotides IL312124A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163256730P 2021-10-18 2021-10-18
PCT/US2022/078266 WO2023069926A1 (en) 2021-10-18 2022-10-18 Eukaryotic cells comprising adenovirus-associated virus polynucleotides

Publications (1)

Publication Number Publication Date
IL312124A true IL312124A (en) 2024-06-01

Family

ID=84389146

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312124A IL312124A (en) 2021-10-18 2022-10-18 Eukaryotic cells containing adenovirus polynucleotides

Country Status (11)

Country Link
US (2) US12234472B2 (cg-RX-API-DMAC7.html)
EP (1) EP4419696A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024537896A (cg-RX-API-DMAC7.html)
KR (1) KR20240099288A (cg-RX-API-DMAC7.html)
CN (1) CN118103517A (cg-RX-API-DMAC7.html)
AU (1) AU2022373653A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234939A1 (cg-RX-API-DMAC7.html)
IL (1) IL312124A (cg-RX-API-DMAC7.html)
MX (1) MX2024004647A (cg-RX-API-DMAC7.html)
TW (1) TW202323529A (cg-RX-API-DMAC7.html)
WO (1) WO2023069926A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR127674A1 (es) 2021-10-18 2024-02-21 Regeneron Pharma Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios
WO2024263705A2 (en) 2023-06-20 2024-12-26 Regeneron Pharmaceuticals, Inc. Methods for purifying filled adeno-associated virus capsids

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5985846A (en) 1995-06-07 1999-11-16 Baylor College Of Medicine Gene therapy for muscular dystrophy
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
WO1998054345A1 (en) 1997-05-30 1998-12-03 Baxter International Inc. Mini-adenoviral vector
IL133510A0 (en) 1998-04-15 2001-04-30 Univ New York State Res Found Selective regulation of adenovirus production
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
US6423544B1 (en) 1998-12-31 2002-07-23 Chiron Corporation Compositions and methods for producing recombinant virions
MY123548A (en) 1999-11-08 2006-05-31 Shell Int Research Method and system for suppressing and controlling slug flow in a multi-phase fluid stream
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
WO2002066620A2 (de) 2001-02-21 2002-08-29 Stefan Kochanek Pigmentepithelzelle des auges, ihre herstellung und verwendung in der therapie einer augen- oder zns-erkrankung
CA2485939C (en) 2002-05-29 2013-10-29 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
WO2005106046A1 (en) 2004-05-03 2005-11-10 Stefan Kochanek Modified viral vector particles
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
WO2007084773A2 (en) * 2006-01-20 2007-07-26 University Of North Carolina At Chapel Hill Enhanced production of infectious parvovirus vectors in insect cells
WO2007133797A2 (en) 2006-05-15 2007-11-22 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
DK2150617T3 (en) 2007-06-04 2015-01-12 Regeneron Pharma Regions with increased expression and stability
US8852926B2 (en) 2007-10-25 2014-10-07 Board Of Trustees Of Southern Illinois University Genetic selection system for identification of MicroRNA target genes
DE102009003439A1 (de) 2009-02-05 2010-08-26 Cevec Pharmaceuticals Gmbh Neue permanente humane Zelllinie
US8734809B2 (en) * 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
WO2011126808A2 (en) * 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9839696B2 (en) 2010-04-30 2017-12-12 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
JP5928843B2 (ja) 2010-08-16 2016-06-01 ツェヴェック ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング インフルエンザウイルスを製造するための永久ヒト羊膜細胞株
EP2662451A1 (en) 2012-05-07 2013-11-13 Stefan Kochanek Nucleic acid construct and use of the same
EP2711428A1 (en) 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
EP3030656B1 (en) 2013-08-06 2018-08-22 Lonza Biologics Plc. Means and methods for the generation of mammalian producer cells for the production of recombinant proteins
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
JP6756700B2 (ja) 2014-03-18 2020-09-16 ユニバーシティ オブ マサチューセッツ 筋萎縮性側索硬化症を処置するためのrAAVベースの組成物および方法
EP3209785B1 (en) 2014-10-23 2019-07-31 Regeneron Pharmaceuticals, Inc. Novel cho integration sites and uses thereof
EP3042952A1 (en) 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
TWI707951B (zh) 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
EP3205719A1 (en) 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603577D0 (en) 2016-03-01 2016-04-13 Oxford Genetics Ltd Promoter
WO2017173043A1 (en) 2016-03-30 2017-10-05 Spark Therapeutics, Inc. Cell line for recombinant protein and/or viral vector production
BR112018071283A2 (pt) 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.
GB2549809C (en) 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
US20190171188A1 (en) 2016-08-10 2019-06-06 Lonza Inc. Biopharmaceutical Batch Recipe Review by Exception
JP7112414B2 (ja) 2017-02-08 2022-08-03 フリードリッヒ ミーシェー インスティトゥート フォー バイオメディカル リサーチ 網膜神経節細胞中の遺伝子の特異的発現のためのプロモーターsynp88
CN119242587A (zh) 2017-02-17 2025-01-03 隆萨有限公司 难以表达的蛋白质的多位点特异性整合细胞
WO2018150271A1 (en) 2017-02-17 2018-08-23 Lonza Ltd. Mammalian cells for producing adeno-associated viruses
CN110419011A (zh) 2017-03-17 2019-11-05 龙沙有限公司 自动化批量数据分析
EP3601581B1 (en) 2017-03-22 2025-04-30 Ultragenyx Pharmaceutical Inc. CELL CULTURE METHODS INVOLVING HDAC INHIBITORS OR REP PROTEINS
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
GB201705927D0 (en) 2017-04-12 2017-05-24 Oxford Genetics Ltd Vector
BR112019021595A2 (pt) 2017-04-18 2020-05-12 Glaxosmithkline Intellectual Property Development Limited Célula produtora de vírus adeno-associado, vetor de ácido nucleico, métodos para produzir uma linhagem de células de empacotamento estável de vírus adeno-associado e uma partícula de vetor de vírus adeno-associado com defeito de replicação, célula de empacotamento de vírus adeno-associado, e, partícula de vetor de vírus adeno-associado com defeito de replicação.
CN110892064A (zh) 2017-07-25 2020-03-17 牛津遗传学有限公司 腺病毒载体
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
EP3456822A1 (en) 2017-09-19 2019-03-20 CEVEC Pharmaceuticals GmbH Inducible aav rep genes
US12123027B2 (en) 2017-10-12 2024-10-22 Ascend Advanced Therapies Limited Life-cycle-defective adenovirus helper viruses, their production and use for producing rAAV
CN111386126B (zh) 2017-10-25 2024-01-30 Nouscom股份公司 真核细胞系
IL275462B2 (en) 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
GB201800903D0 (en) 2018-01-19 2018-03-07 Oxford Genetics Ltd Vectors
WO2019157239A1 (en) 2018-02-08 2019-08-15 David Kiewlich Plasmid vectors for expression of large nucleic acid transgenes
GB201802122D0 (en) 2018-02-09 2018-03-28 Univ Oxford Innovation Ltd Product and use
GB201814590D0 (en) 2018-09-07 2018-10-24 Oxford Biomedica Ltd Viral vector production system
EP3597172A1 (en) 2018-07-16 2020-01-22 Kao Germany GmbH Hair treatment composition
WO2020033842A1 (en) * 2018-08-10 2020-02-13 Regenxbio Inc. Scalable method for recombinant aav production
EP3841193A1 (en) 2018-08-21 2021-06-30 Lonza Ltd. A process for creating reference data for predicting concentrations of quality attributes
GB201814141D0 (en) 2018-08-30 2018-10-17 Univ Oxford Innovation Ltd Method and compositions for producing a virus
JP7549582B2 (ja) 2018-10-01 2024-09-11 ロンザ リミテッド 予測可能かつ安定な導入遺伝子発現を有するssi細胞および形成の方法
US20210388343A1 (en) 2018-10-17 2021-12-16 Children's Medical Research Institute Nucleic acid molecules and methods for aav vector selection
GB201816919D0 (en) 2018-10-17 2018-11-28 Glaxosmithkline Ip Dev Ltd Adeno-associated viral vector producer cell lines
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
JP7598864B2 (ja) 2018-12-21 2024-12-12 ロンザ ウォーカーズヴィル,インコーポレーテッド ウイルスベクターの自動産生方法
EP3980544A1 (en) 2018-12-21 2022-04-13 F. Hoffmann-La Roche AG Targeted integration of nucleic acids
SG11202106217TA (en) * 2018-12-21 2021-07-29 Lonza Walkersville Inc Adeno-associated virus (aav) producer cell line and related methods
GB201901571D0 (en) 2019-02-05 2019-03-27 Oxford Genetics Ltd Inducible AAV sysyem
GB201902068D0 (en) 2019-02-14 2019-04-03 Cambridge Entpr Ltd Methods of reactivating proliferative capacity non-proliferative tissues
US20220154174A1 (en) 2019-03-08 2022-05-19 Oxford Genetics Limited Method of Selecting for Antibodies
US12018288B2 (en) 2019-04-12 2024-06-25 Ultragenyx Pharmaceutical Inc. Engineered producer cell lines and methods of making and using the same
AU2020275884B2 (en) 2019-05-16 2026-05-14 Trustees Of Boston University Regulated synthetic gene expression systems
EP3976806A1 (en) 2019-05-30 2022-04-06 Solidus Biosciences, Inc. Recombinant herpesvirales vector
KR20220118436A (ko) 2019-12-19 2022-08-25 론자 워커스빌 아이엔씨. 바이러스 벡터의 자동화된 생산
EP4090750A4 (en) 2020-01-17 2024-03-13 Asklepios Biopharmaceutical, Inc. RECOMBINANT AAV PRODUCTION
GB202001484D0 (en) 2020-02-04 2020-03-18 Oxford Genetics Ltd DNA amplification method
AU2021217799A1 (en) 2020-02-04 2022-07-21 Oxford Genetics Limited Process for making adenoassociated viral vectors
US20230235353A1 (en) 2020-03-19 2023-07-27 Ultragenyx Pharmaceutical Inc. Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
KR20230017799A (ko) 2020-05-15 2023-02-06 아이벡스솔, 아이엔씨. 세포 및 유전자 요법을 위한 안정한 바이러스 벡터 생산자 세포를 생산하기 위한 조성물 및 방법
CN113699147B (zh) 2020-05-22 2023-06-09 深圳市深研生物科技有限公司 基于四环素和Cumate的共调控序列
WO2022020712A1 (en) 2020-07-24 2022-01-27 Regents Of The University Of Minnesota Cell lines for recombinant aav production and aav-implemented protein production
US20230357794A1 (en) 2020-08-21 2023-11-09 Oxford Genetics Limited Process for making a recombinant aav library
GB202013060D0 (en) 2020-08-21 2020-10-07 Oxford Genetics Ltd Cell line
GB202013057D0 (en) 2020-08-21 2020-10-07 Oxford Genetics Ltd Method of making recombinant aavs
EP4006141A1 (en) * 2020-11-25 2022-06-01 CEVEC Pharmaceuticals GmbH Method for the production of aav
EP4291665A1 (en) 2021-02-11 2023-12-20 Lonza Houston Inc. Adeno-associated virus (aav) production
JP2024517104A (ja) 2021-04-19 2024-04-19 オックスフォード ジェネティクス リミテッド Careエレメントを用いたdna増幅方法
US20230257831A1 (en) 2021-09-01 2023-08-17 Oxford Genetics Limited Method for determining aav titre
AR127674A1 (es) 2021-10-18 2024-02-21 Regeneron Pharma Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios
CN118159660A (zh) 2021-10-18 2024-06-07 瑞泽恩制药公司 多核苷酸的受控转录
WO2023173105A2 (en) 2022-03-10 2023-09-14 Saliogen Therapeutics, Inc. Tetracycline inducer/repressor system and simplified viral particle production

Also Published As

Publication number Publication date
MX2024004647A (es) 2024-05-02
TW202323529A (zh) 2023-06-16
WO2023069926A1 (en) 2023-04-27
CN118103517A (zh) 2024-05-28
CA3234939A1 (en) 2023-04-27
US12234472B2 (en) 2025-02-25
JP2024537896A (ja) 2024-10-16
US20250154524A1 (en) 2025-05-15
KR20240099288A (ko) 2024-06-28
EP4419696A1 (en) 2024-08-28
US20230193312A1 (en) 2023-06-22
AU2022373653A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
IL279157A (en) Circular RNA for translation in eukaryotic cells
IL274200A (en) Implantable methods, compositions and components containing active cells
EP3386015A4 (en) Cathode active material for secondary battery, and secondary battery comprising same
EP3845564A4 (en) ENHANCED THERAPEUTIC T LYMPHOCYTE
EP3331072A4 (en) Composition for forming secondary battery cathode, and secondary battery cathode and secondary battery, which are manufactured using same
PL3386009T3 (pl) Materiał aktywny elektrody dodatniej dla baterii akumulatorowej, elektroda dodatnia, dla baterii akumulatorowej, zawierającej to samo, i bateria akumulatorowa
EP3249723A4 (en) Cathode active material for secondary battery and secondary battery comprising same
EP3305753A4 (en) LITHIUM SALT COMPOUND, WATER-FREE ELECTROLYTE SOLUTION USING THEREOF, LITHIUM ION SECONDARY BATTERY AND LITHIUM ION CONDENSER
EP3358662A4 (en) Binder composition, non-aqueous electrolyte secondary battery electrode, and non-aqueous electrolyte secondary battery
IL288221A (en) Immune cells are safe
EP3273519A4 (en) Non-aqueous electrolyte, and non-aqueous electrolyte secondary cell
LT3551960T (lt) Zonos blokavimo ryšio delsos kompensavimas
EP3595059A4 (en) POSITIVE ELECTRODE ACTIVE MATERIAL AND CELL
EP3258529A4 (en) Nonaqueous-electrolyte secondary cell, and positive electrode of nonaqueous-electrolyte secondary cell
EP3252861A4 (en) Non-aqueous electrolyte solution, and non-aqueous-electrolyte secondary cell using same
EP3282502A4 (en) Electrode, electrode group and nonaqueous electrolyte battery
EP3309882A4 (en) Cathode composition, cathode and fuel cell including same
GB2617521B (en) Improved electrode arrangement
GB201810165D0 (en) Surgical assembly, system and electrode assembly
SG11202006726UA (en) Recombinant vaccinia virus and pharmaceutical composition comprising same
GB2592481B (en) Cell preparation
GB201904971D0 (en) Cell
HK40113202A (en) Eukaryotic cells comprising adenovirus-associated virus polynucleotides
EP3782623A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PROTECTION OF HMYOCARDIAL CELLS
EP3255709A4 (en) Positive electrode active material and secondary battery comprising same